Glaxo Group Limited v. M/S. Therapia Sanjeevani LLP and Anr.
Case brief
What is this about?
Delhi High Court commercial suit decree CS(COMM) 241/2026 dated 13 March 2026, Justice Jyoti Singh; parties Glaxo Group Limited v. M/S. Therapia Sanjeevani LLP and Anr.; marks LANOXIN v. LINOCIN (pharmaceutical mark conflict); consent-based decree of permanent injunction restraining manufacture, export, sale, offer for sale of goods/services bearing LINOCIN or deceptively similar marks; withdrawal of trade mark registration Application No. 7192488 within three weeks; sell-off/exhaustion of existing stock permitted until 30.06.2026 with affidavit disclosure within one week; refund of entire court fees under Court Fees Act, 1870; decree sheet directions; suit disposed of with pending applications; plaintiff advocates Urfee Roomi, Ritesh Kumar, Arpit Singhal (Sujata Chaudhri IP Attorneys); defendant advocates Rahul Vidhani, Dhruv Sikka.
What did the court decide?
Suit decreed in terms of paragraph 55(a) to (d) restraining Defendants from using LINOCIN or any mark identical or deceptively similar to LANOXIN; Defendants to withdraw trade mark registration Application No. 7192488 within three weeks; per consent terms recorded in court, Defendants permitted to exhaust existing stock on or before 30.06.2026 with stock details on affidavit within one week and immediate cessation of fresh manufacture under the impugned mark; Plaintiff gave up all other reliefs and is held entitled to refund of entire court fees per Court Fees Act, 1870; Registry directed to draw up the decree sheet; suit disposed of along with pending applications.